<p>全球市場經歷了動盪的一週，主要指數如標準普爾 500 和道瓊斯工業平均指數在地緣政治緊張局勢和經濟更新的影響下收盤下跌。在如此波動的時期，投資者通常會在市場中尋找不太傳統的機會，例如便士股票。儘管 “便士股票” 這個術語可能顯得過時，但它仍然代表着一些較小或新興的公司，這些公司在強大的財務支持下可以提供可觀的價值。</p>
<h3>全球十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.42</td>
<td>HK$878.3M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Foresight Group Holdings (LSE:FSG)</td>
<td>£4.28</td>
<td>£489.57M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.99</td>
<td>A$473.21M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.48</td>
<td>HK$2.04B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.35</td>
<td>SGD13.18B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Integrated Diagnostics Holdings (LSE:IDHC)</td>
<td>$0.63</td>
<td>$366.24M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>EDU Holdings (ASX:EDU)</td>
<td>A$0.76</td>
<td>A$107.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>REDtone Digital Berhad (KLSE:REDTONE)</td>
<td>MYR0.37</td>
<td>MYR285.99M</td>
<td>✅ 3 ⚠️ 4 查看分析 </td>
</tr>
<tr>
<td>Begbies Traynor Group (AIM:BEG)</td>
<td>£1.20</td>
<td>£193.11M</td>
<td>✅ 6 ⚠️ 1 查看分析 </td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球便士股票篩選器中的 3521 只股票的完整列表。</p>
<p>讓我們探索篩選結果中的幾個突出選項。</p>
<h2>雍禾醫療集團 (SEHK:2279)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 雍禾醫療集團有限公司在中國運營，提供與頭髮相關的醫療服務，市值約為 HK$10.4 億。</p>
<p><strong>運營：</strong> 該公司主要通過提供植髮服務產生收入，金額為 CN¥17.7 億。</p>
<p><strong>市值：</strong> HK$10.4B</p>
<p>雍禾醫療集團在中國的頭髮相關醫療行業運營，目前尚未盈利，但保持強勁的財務狀況，現金超過債務，短期資產超過其負債。該公司的交易價格顯著低於估計的公允價值，並且與同行相比提供了良好的相對價值。儘管股本回報率為負，雍禾擁有超過三年的充足現金流，支持其正的自由現金流。預計收益將以 157.85% 的年率大幅增長。管理團隊和董事會經驗豐富，平均任期超過四年。</p>
<ul>
<li>在我們的財務健康報告中更詳細地瞭解雍禾醫療集團的潛力。</li>
<li>通過我們的公司收益預估報告獲取雍禾醫療集團的前景和預期表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b5f4e00a-6633-419e-8e99-83a3baa2304a/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b5f4e00a-6633-419e-8e99-83a3baa2304a/chart/debt-equity-history-analysis"/></p>
<p>SEHK:2279 債務與股本歷史及分析截至 2026 年 1 月</p>
<h2>福源金屬製造 (SGX:BTG)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 福源金屬製造有限公司是一家投資控股公司，主要在印度尼西亞、馬來西亞、緬甸和新加坡交易鋼鐵產品，市值為 SGD1.827 億。</p>
<p><strong>運營：</strong> 公司的收入主要來自兩個主要部門：貿易，貢獻 SGD5639 萬，和製造，貢獻 SGD1.6949 億。</p>
<p><strong>市值：</strong> SGD1.827M</p>
<p>福源金屬製造有限公司展現出財務穩定性，其短期資產超過長期和短期負債，且債務與股本比率在五年內顯著下降。該公司報告截至 2025 年 9 月的九個月銷售額為 SGD1.3027 億，淨收入達到 SGD734 萬，反映出與過去五年平均相比，28.3% 的強勁收益增長。儘管交易價格遠低於估計的公允價值，福源金屬的股息歷史不穩定，但目前提議每股 SGD0.015 的免税股息，將於 2026 年 2 月支付。</p>
<ul>
<li>通過我們的綜合資產負債表健康報告深入瞭解福源金屬製造的複雜性。</li>
<li>通過查看我們的歷史業績報告獲取福源金屬製造的歷史結果的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/57f07631-fa49-4336-b909-b131655a31ff/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/57f07631-fa49-4336-b909-b131655a31ff/chart/financial-position-analysis"/></p>
<p>SGX:BTG 財務狀況分析截至 2026 年 1 月</p>
<h2>德展健康 (SZSE:000813)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 德展健康有限公司專注於心血管和腦血管藥物的研究、開發、生產和銷售，市值為 CN¥79.5 億。</p>
<p><strong>運營：</strong> 目前，該公司沒有報告的收入部門。</p>
<p><strong>市值：</strong> CN¥79.5B</p>
<p>德展健康的市值為 CN¥79.5 億，專注於中國的心血管和腦血管藥物，但仍處於無收入狀態。該公司處於虧損狀態，五年來虧損年均增長 43.6%。儘管如此，德展的短期資產為 CN¥32 億，顯著超過其短期和長期負債，表明強勁的流動性管理。此外，債務水平管理良好，現金超過總債務，經營現金流覆蓋 32.1% 的債務義務。管理層經驗豐富，平均任期為 2.4 年，而董事會的平均任期為 4.4 年。</p>
<ul>
<li>點擊探索我們在德展健康財務健康報告中的詳細發現。</li>
<li>查看我們的歷史業績報告，以獲取德展健康的業績記錄的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a4d8913f-ce49-491b-aa81-bca9e7c5744c/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a4d8913f-ce49-491b-aa81-bca9e7c5744c/chart/financial-position-analysis"/></p>
<p>SZSE:000813 財務狀況分析截至 2026 年 1 月</p>
<h2>主要結論</h2>
<ul>
<li>在這裏探索我們全球便士股票篩選器中的 3,521 個名稱。</li>
<li>尋找新的視角？發現 14 家在 COVID 後生存並蓬勃發展的公司，它們具備應對特朗普關税的正確條件。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不應被視為財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

德展健康

雍禾醫療

福源金屬製造

<p>全球市場面臨波動，主要指數因地緣政治緊張局勢而下跌。投資者開始關注便士股票，這些股票代表了具有潛在價值的小型公司。值得注意的便士股票包括雍禾醫療、福源金屬製造和德展健康，每個公司都有獨特的財務狀況和增長前景。雍禾醫療專注於中國的頭髮健康，儘管尚未盈利，但現金流強勁。福源金屬製造從事鋼鐵產品交易，展現出財務穩定性和增長潛力。德展健康專注於心血管藥物，仍處於無收入階段，但保持強勁的流動性。這些股票在市場不確定性中提供了機會</p>

<p>Global markets have experienced a turbulent week, with major indices like the S&amp;P 500 and Dow Jones Industrial Average closing lower amid geopolitical tensions and economic updates. In such volatile times, investors often seek opportunities in less conventional areas of the market, such as penny stocks. Although the term 'penny stock' may seem outdated, it still represents smaller or emerging companies that can offer substantial value when backed by strong financials.</p>
<div class="lb-trans"><p>全球市場經歷了動盪的一週，主要指數如標準普爾 500 和道瓊斯工業平均指數在地緣政治緊張局勢和經濟更新的影響下收盤下跌。在如此波動的時期，投資者通常會在市場中尋找不太傳統的機會，例如便士股票。儘管 “便士股票” 這個術語可能顯得過時，但它仍然代表着一些較小或新興的公司，這些公司在強大的財務支持下可以提供可觀的價值。</p>
</div><h3>Top 10 Penny Stocks Globally</h3>
<div class="lb-trans"><h3>全球十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.42</td>
<td>HK$878.3M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Foresight Group Holdings (LSE:FSG)</td>
<td>£4.28</td>
<td>£489.57M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.99</td>
<td>A$473.21M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.48</td>
<td>HK$2.04B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.35</td>
<td>SGD13.18B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Integrated Diagnostics Holdings (LSE:IDHC)</td>
<td>$0.63</td>
<td>$366.24M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>EDU Holdings (ASX:EDU)</td>
<td>A$0.76</td>
<td>A$107.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>REDtone Digital Berhad (KLSE:REDTONE)</td>
<td>MYR0.37</td>
<td>MYR285.99M</td>
<td>✅ 3 ⚠️ 4 View Analysis &gt;</td>
</tr>
<tr>
<td>Begbies Traynor Group (AIM:BEG)</td>
<td>£1.20</td>
<td>£193.11M</td>
<td>✅ 6 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.42</td>
<td>HK$878.3M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Foresight Group Holdings (LSE:FSG)</td>
<td>£4.28</td>
<td>£489.57M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.99</td>
<td>A$473.21M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.48</td>
<td>HK$2.04B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.35</td>
<td>SGD13.18B</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Integrated Diagnostics Holdings (LSE:IDHC)</td>
<td>$0.63</td>
<td>$366.24M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>EDU Holdings (ASX:EDU)</td>
<td>A$0.76</td>
<td>A$107.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>REDtone Digital Berhad (KLSE:REDTONE)</td>
<td>MYR0.37</td>
<td>MYR285.99M</td>
<td>✅ 3 ⚠️ 4 查看分析 </td>
</tr>
<tr>
<td>Begbies Traynor Group (AIM:BEG)</td>
<td>£1.20</td>
<td>£193.11M</td>
<td>✅ 6 ⚠️ 1 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 3,521 stocks from our Global Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球便士股票篩選器中的 3521 只股票的完整列表。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>讓我們探索篩選結果中的幾個突出選項。</p>
</div><h2>Yonghe Medical Group (SEHK:2279)</h2>
<div class="lb-trans"><h2>雍禾醫療集團 (SEHK:2279)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Yonghe Medical Group Co., Ltd. operates in China, offering hair-related healthcare services, with a market cap of approximately HK$1.04 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 雍禾醫療集團有限公司在中國運營，提供與頭髮相關的醫療服務，市值約為 HK$10.4 億。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from the provision of hair transplant services, amounting to CN¥1.77 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過提供植髮服務產生收入，金額為 CN¥17.7 億。</p>
</div><p><strong>Market Cap:</strong> HK$1.04B</p>
<div class="lb-trans"><p><strong>市值：</strong> HK$10.4B</p>
</div><p>Yonghe Medical Group, operating in the hair-related healthcare sector in China, is currently unprofitable but maintains a strong financial position with more cash than debt and short-term assets exceeding its liabilities. The company trades significantly below estimated fair value and offers good relative value compared to peers. Despite negative returns on equity, Yonghe has a sufficient cash runway for over three years, supported by positive free cash flow. Earnings are forecasted to grow substantially at 157.85% annually. The management team and board are experienced, with tenures averaging over four years each.</p>
<div class="lb-trans"><p>雍禾醫療集團在中國的頭髮相關醫療行業運營，目前尚未盈利，但保持強勁的財務狀況，現金超過債務，短期資產超過其負債。該公司的交易價格顯著低於估計的公允價值，並且與同行相比提供了良好的相對價值。儘管股本回報率為負，雍禾擁有超過三年的充足現金流，支持其正的自由現金流。預計收益將以 157.85% 的年率大幅增長。管理團隊和董事會經驗豐富，平均任期超過四年。</p>
</div><ul>
<li>Take a closer look at Yonghe Medical Group's potential here in our financial health report.</li>
<li>Gain insights into Yonghe Medical Group's outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的財務健康報告中更詳細地瞭解雍禾醫療集團的潛力。</li>
<li>通過我們的公司收益預估報告獲取雍禾醫療集團的前景和預期表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b5f4e00a-6633-419e-8e99-83a3baa2304a/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/b5f4e00a-6633-419e-8e99-83a3baa2304a/chart/debt-equity-history-analysis"/></p>
<p>SEHK:2279 Debt to Equity History and Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SEHK:2279 債務與股本歷史及分析截至 2026 年 1 月</p>
</div><h2>HG Metal Manufacturing (SGX:BTG)</h2>
<div class="lb-trans"><h2>福源金屬製造 (SGX:BTG)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> HG Metal Manufacturing Limited is an investment holding company that primarily trades in steel products across Indonesia, Malaysia, Myanmar, and Singapore with a market cap of SGD182.70 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> 福源金屬製造有限公司是一家投資控股公司，主要在印度尼西亞、馬來西亞、緬甸和新加坡交易鋼鐵產品，市值為 SGD1.827 億。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from two main segments: Trading, which contributes SGD56.39 million, and Manufacturing, accounting for SGD169.49 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自兩個主要部門：貿易，貢獻 SGD5639 萬，和製造，貢獻 SGD1.6949 億。</p>
</div><p><strong>Market Cap:</strong> SGD182.7M</p>
<div class="lb-trans"><p><strong>市值：</strong> SGD1.827M</p>
</div><p>HG Metal Manufacturing Limited demonstrates financial stability with its short-term assets surpassing both long-term and short-term liabilities, and a debt-to-equity ratio that has decreased significantly over five years. The company reported sales of SGD 130.27 million for the nine months ending September 2025, with net income reaching SGD 7.34 million, reflecting a robust earnings growth of 28.3% over the past year compared to its five-year average. While trading well below estimated fair value, HG Metal's dividend history is unstable but currently proposes a tax-exempt dividend of SGD 0.015 per share payable in February 2026.</p>
<div class="lb-trans"><p>福源金屬製造有限公司展現出財務穩定性，其短期資產超過長期和短期負債，且債務與股本比率在五年內顯著下降。該公司報告截至 2025 年 9 月的九個月銷售額為 SGD1.3027 億，淨收入達到 SGD734 萬，反映出與過去五年平均相比，28.3% 的強勁收益增長。儘管交易價格遠低於估計的公允價值，福源金屬的股息歷史不穩定，但目前提議每股 SGD0.015 的免税股息，將於 2026 年 2 月支付。</p>
</div><ul>
<li>Navigate through the intricacies of HG Metal Manufacturing with our comprehensive balance sheet health report here.</li>
<li>Gain insights into HG Metal Manufacturing's historical outcomes by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的綜合資產負債表健康報告深入瞭解福源金屬製造的複雜性。</li>
<li>通過查看我們的歷史業績報告獲取福源金屬製造的歷史結果的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/57f07631-fa49-4336-b909-b131655a31ff/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/57f07631-fa49-4336-b909-b131655a31ff/chart/financial-position-analysis"/></p>
<p>SGX:BTG Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SGX:BTG 財務狀況分析截至 2026 年 1 月</p>
</div><h2>Dezhan Healthcare (SZSE:000813)</h2>
<div class="lb-trans"><h2>德展健康 (SZSE:000813)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Dezhan Healthcare Company Limited focuses on the research, development, manufacture, and sale of cardiovascular and cerebrovascular drugs in China with a market cap of CN¥7.95 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 德展健康有限公司專注於心血管和腦血管藥物的研究、開發、生產和銷售，市值為 CN¥79.5 億。</p>
</div><p><strong>Operations:</strong> Currently, there are no reported revenue segments for the company.</p>
<div class="lb-trans"><p><strong>運營：</strong> 目前，該公司沒有報告的收入部門。</p>
</div><p><strong>Market Cap:</strong> CN¥7.95B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥79.5B</p>
</div><p>Dezhan Healthcare, with a market cap of CN¥7.95 billion, focuses on cardiovascular and cerebrovascular drugs in China but remains pre-revenue. The company is unprofitable with losses increasing at 43.6% annually over five years. Despite this, Dezhan's short-term assets of CN¥3.2 billion significantly exceed both its short-term and long-term liabilities, suggesting strong liquidity management. Additionally, the debt level is well-managed as cash surpasses total debt and operating cash flow covers 32.1% of the debt obligations. Management demonstrates experience with an average tenure of 2.4 years, while the board averages 4.4 years in tenure.</p>
<div class="lb-trans"><p>德展健康的市值為 CN¥79.5 億，專注於中國的心血管和腦血管藥物，但仍處於無收入狀態。該公司處於虧損狀態，五年來虧損年均增長 43.6%。儘管如此，德展的短期資產為 CN¥32 億，顯著超過其短期和長期負債，表明強勁的流動性管理。此外，債務水平管理良好，現金超過總債務，經營現金流覆蓋 32.1% 的債務義務。管理層經驗豐富，平均任期為 2.4 年，而董事會的平均任期為 4.4 年。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Dezhan Healthcare's financial health report.</li>
<li>Review our historical performance report to gain insights into Dezhan Healthcare's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在德展健康財務健康報告中的詳細發現。</li>
<li>查看我們的歷史業績報告，以獲取德展健康的業績記錄的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a4d8913f-ce49-491b-aa81-bca9e7c5744c/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/a4d8913f-ce49-491b-aa81-bca9e7c5744c/chart/financial-position-analysis"/></p>
<p>SZSE:000813 Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>SZSE:000813 財務狀況分析截至 2026 年 1 月</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>主要結論</h2>
</div><ul>
<li>Explore the 3,521 names from our Global Penny Stocks screener here.</li>
<li>Searching for a Fresh Perspective? Uncover 14 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏探索我們全球便士股票篩選器中的 3,521 個名稱。</li>
<li>尋找新的視角？發現 14 家在 COVID 後生存並蓬勃發展的公司，它們具備應對特朗普關税的正確條件。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不應被視為財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

全球便士股：市值低於 20 億美元的三大隱藏寶石